Okült Hepatit B Virus Enfeksiyonu: Virolojik ve Moleküler Mekanizmalar

Year 2016, Volume: 6 Issue: 11, 22 - 42, 01.06.2016

Bülent Çakal

Abstract

Okült
Hepatitis B Virus (HBV) enfeksiyonu (Occult HBV infection; OBİ) serum HBV DNA
statüsü dikkate alınmaksızın mevcut serolojik testler ile HBV yüzey antijeni
(HBsAg) negatif tespit edilen bireylerin karaciğerinde HBV genomunun uzun
süreli persistan varlığı olarak tanımlanır. OBİ’nin Hepatoselüler karsinoma (HSK) riski ile kronik
karaciğer hastalığının (KKH) progresyonunun artışına sebep olabilen önemli bir
risk faktörü olduğu hipotez edilmektedir. OBİ virüse ve infekte
konağa ait faktörler ile çevresel faktörlerin zemininde gelişen genetik, epigenetik
ve immünolojik mekanizmaların karşılıklı etkileşimi ile şekillenen, kronik HBV
enfeksiyonunun doğal seyri içerisinde muhtemelen safhalarından biri olarak
değerlendirilmesine karşın, HBV enfeksiyonunun bu özgün formuna neden olan
mekanizmalar henüz tam olarak belirlenememiştir. Bu derlemede OBİ’nin virolojik
özellikleri ve moleküler mekanizmalarının aydınlatılmasına yönelik bilimsel
literatürün irdelenmesi amaçlanmıştır. 

Keywords

okült hepatitis b, viroloji, enfeksyon

References

• 1. Lavanchy, D. Hepatitis B. Virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97–107. 2. World Health Organization. http://www.who.int/mediacentre/factsheets/fs204/en/ erişim 12 Ocak 2015 3. World Health Organization. http://www.who.int/mediacentre/factsheets/fs297/en/ (erişim 12 Ocak 2015) 4. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980; 303:833-41. 5. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial amoung homosexual men. Ann Intern Med. 1982; 97:362-6. 6. Crosnier J, Jungers P, Courouc‚ AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebocontrolled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, medical staff. Lancet. 1981; 1:455-9. 7. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature. 1985; 17:489-95. 8. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus – A prospective study of 22707 men in Taiwan. Lancet. 1981; 2:1129-33. 9. Beasley RP. Hepatitis B virus: The major etiology of hepatocellular carcinoma. Cancer. 1988; 61:1942-56. 10. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet .2003; 62: 2089–2094. 11. Shi J, Zhu L, Liu S, Xie WF. A metaanalysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005; 92: 607–612. 12. Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol. 1998; 93: 896–900. 13. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68:105-112. 14. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978; 298:1379-83. 15. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999; 341: 22-6. 16. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al.Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008; 49: 652-7. 17. Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol. 2014; 20(20): 5951-61. 18. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57:167-85. 19. Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011; 32: 1122-32. 20. De Mitri MS, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer. 2010; 46:2178–86. 21. Fang Y, Shang Q-L, Liu J-Y, Li D, Xu W-Z, Teng X, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009; 58: 383–8. 22. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology. 2001; 34(1):194–203. 23. Ohba K, Kubo S, Tamori A, Hirohashi K, Tanaka H, Shuto T, et al. Previous or occult hepatitis B virus infection in hepatitis B surface antigen negative and anti-hepatitis C negative patients with hepatocellular carcinoma. Surg Today. 2004; 34 (10):842–8. 24. Will H, Reiser W, Weimer T, Pfaff E, Buscher M, Sprengle R, et al. Replication strategy of human hepatitis B virus. J Virol. 1987; 61:904-11. 25. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008; 134: 235-49. 26. Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis. 2007; 11:685-706. 27. Locarnini S, Zoulim F. Molecular genetics of HBV infection Antivir Ther. 2010; 15 Suppl 3:3-14. 28. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2014; 2014; 3:e05570. 29. Schaller, H., and M. Fischer. Transcriptional control of hepadnavirus gene expression. Curr. Top Microbiol Immunol. 1991; 168:21-39. 30. Yen, T S B. Regulation of hepatitis B virus gene expression. Semin Virol. 1993; 4:33-42. 31. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell. 1982; 29: 403-15. 32. Raney AK, Johnson JL, Palmer CNA, McLachlan A. Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter. J Virol. 1997; 71:1058-71. 33. Zhou S, Standring DN. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. PNAS. 1992; 89:10046-50. 34. Juergen Beck, Michael Nassal Hepatitis B virus replication World J Gastroenterol. 2007; 13(1): 48-64. 35. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005; 32:102-12. 36. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda S K. Occult hepatitis B virus infection in chronic liver disease: fulllength genome and analysis of mutant surface promoter. Gastroenterology. 2004; 127(5):1356–71. 37. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 1998; 27:1736-42. 38. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005; 42:302-308. 39. Teresa Pollicino, Giovanni Raimondo. Occult Hepatitis B Infection. Journal of Hepatology 2014; 61:688-9. 40. Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008; 49:652-7. 41. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002; 2:479-86. 42. Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol. 2007; 13:5682-6. 43. Michalak TI, Mulrooney PM, Coffin CS. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol. 2004; 78:1730–8. 44. Raimondo G, Caccamo G, Filomia R, Pollicino T Occult HBV infection. Semin Immunopathol. 2013; 35:39–52. 45. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137:1593–1608. 46. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012; 25:142-63. 47. Hui-Lan Zhu, Xu Li, Jun Li, Zhen-Hua Zhang Genetic variation of occult hepatitis B virus infection. World J Gastroenterol. 2016; 22(13):3531-46. 48. R. A. A. Pondé Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis. 2015; 34:1709–31. 49. Fang Y, Teng X, Xu W, Li D, Zhao H, Fu L, et al. Molecular Characterization and Functional Analysis of Occult Hepatitis B Virus Infection in Chinese Patients Infected With Genotype C. J Med Virol. 2009; 81:826–35. 50. Candotti D, Lin CK, Belkhiri D, Sakuldamrongpanich T, Biswas S, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut. 2012; 61:1744–53. 51. Allain JP, Belkhiri D, Vermeulen M, Crookes R, Cable R, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology. 2009; 49: 1868–76. 52. Seeger C, Mason W Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64(1):51–68. 53. Weber B. The diagnostic and clinical impact of the genetic variability of the s gene of hepatitis B virus. J LabMed. 2004; 28(1):56–69. 54. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 1997; 4(l1):11–20. 55. Seddigh-Tonekaboni S, Waters JA, Jeffers S, Gehrke R, Ofenloch B, Horsch A, et al. Effect of variation in the common “a” determinant on the antigenicity of hepatitis B surface antigen. J Med Virol. 2000; 60:113–21. 56. Waters J, Kennedy M, Voet P, Hauser P, Petre J, Carman W, Thomas H Loss of the common ‘a’ determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest. 1992; 90:2543–47. 57. Ma Q, Wang Y. Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen. J Med Virol. 2012; 84:198–206. 58. Bruce S, Murray K. Mutations of some critical amino acid residues in the hepatitis B virus surface antigen. J Med Virol. 1995; 46:157–61. 59. Antoni B, Rodriguez-Crespo I, Gomez-Gutierrez J, Nieto M, Peterson D, Avilanes F. Site-directed mutagenesis of cysteine residues of hepatitis B surface antigen. Analysis of two single mutants and the double mutant. Eur J Biochem. 1994; 222:121–27. 60. Tian Y, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, Yang D. The amino acid residues at positions 120 to 123 are crucial for theantigenicity of hepatitis B surface antigen. J Clin Microbiol. 2007; 45(9):2971-8. 61. Osiowy C Detection of HBsAg mutants. J Med Virol. 2006; 78:48–51. 62. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-9. 63. Huang CH, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. Journal of Hepatology. 2012; 57:720–9. 64. Uchida T, Shimojima S, Gotoh K, Shikata T, Mima S. Pathology of livers infected with ‘’silent’’ hepatitis B virus mutant. Liver. 1994; 14:251–6. 65. Fukuda R, Ishimura N, Kushiyama Y, Moriyama N, Ishihara S, Chowdhury A, et al. Hepatitis B virus with X gene mutation is associated with the majority of serologically ‘’silent’’ non-B, non-C chronic hepatitis. Microbiol Immunol. 1996; 40:481–8. 66. Tang H, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci. 2006; 97(10):977–83. 67. Wei Y, Neuveut C, Tiollais P, Buendia MA. Molecular biology of the hepatitis B virus and role of the X gene. Pathol Biol. 2010; 58(4):267–72. 68. Weinberger KM, Bauer T, Böhm S, Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol. 2000; 81:1165–74 69. Chen SY, Kao CF, Chen CM, Shih CM, Hsu MJ, Chao CH, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003; 278:591–607 70. LusidaMI, Sakugawa H, Motroko N-F, Muluanto S, Handajani R, Boediwarsono SPB, Genotype and subtype analyses of hepatitis B virus (HBV) and possible co-infection of HBVand hepatitis c virus (HCV) or hepatitis D virus (HDV) in blood donors, patients with chronic liver disease and patients on hemodialysis is Surabaya, Indonesia. Microbiol Immunol. 2003; 47(12):969–75. 71. Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol. 2005; 4:100–106 48. 72. Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009; 50:46–55. 73. McClary H, Koch R, Chisari FV, Guidotti LG. Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med. 2000; 92:289–94. 74. Tan WS, Dyson MR, Murray K. Two distinct segments of the hepatitis B virus surface antigen contribute synergistically to its association with the viral core particles. J Mol Biol. 1999; 286:797–808 75. Loffler-Mary H, Dumortier J, Klentsch-Zimmer C, Prange R. Hepatitis B virus assembly is sensitive to changes in the cytosolic S loop of the envelope proteins. Virology. 2000; 270:358–67 76. Mangold CT, Streeck RE. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol. 1993; 67:4588–97. 77. Biswas S, Candotti D, Allain J-P Specific amino acid substitutions in the S protein prevent its excretion in vitro and maycontribute to occult hepatitis B virus infection. J Virol. 2013 87(14): 7882–92. 78. Chua PK, Wang RY, Lin MH, Masuda T, Suk FM, Shih C. Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus. J Virol 2005; 79:13483–96. 79. Melegari M, Pier PS,Wands JR. The small envelope protein is required for secretions of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol. 1997; 7(71):5449-54. 80. Bock C, Tillmann H, Manns M, Trautwein C. The pre-S region determines the intracellular localization and appearance of hepatitis B virus. Hepatology. 1999; 30(2):517–25. 81. Ou JH, RutterWJ (1987) Regulation of secretion of the hepatitis B virus major surface antigen by the preS-1 protein. J Virol 61:782–6. 82. Sengupta S, Rehman S, Durgapal H, Acharya S, Panda S. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. J Med Virol. 2007; 79:220–8. 83. Zhou D-X, Yen TS. The hepatitis B virus S promoter comprises a CCAAT motif and two initiation regions. J Biol Chem. 1991; 226(34):23416–21 84. Lu CC, Yen TS. Activation of the hepatitis B virus s promoter by transcription factor NF-Y via a CCAAT welement. Virology. 1996; 225:387–394. 85. Baumert T, Kock J, Blum H. A novel target of hepatitis B virus mutations: splicing of surface RNA. Hepatology. 2005; 45(1):21–4. 86. Zu Putlitz J, Tong S, Wands JR. A short region in the genome of hepatitis B virus is critical for maintenance of high transcript levels. Virology. 1999; 254(2):245–256. 87. Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Günther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology. 2005; 42:93-103. 88. Schmitt S, Glebe D, Tolle T, Lochnit G, Linder D, Geyer R, Gerlich W. Structure of pre-S2 N- and O-linked glycans in surface proteins from different genotypes of hepatitis B virus. J Gen Virol. 2004; 85:2045–53. 89. Ito K, Qin Y, GuarnieriM, Garcia T, Kwei K,MizokamiM, et al. Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol. 2010; 84(24):12850–61. 90. Wu C, Zhang X, Tian Y, Song J, Yang D, Roggendorf M, et al. Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. J Gen Virol 2010; 91: 483-92. 91. Lu X,Mehta A, Dwek R, Butters T, Block T. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virology. 1995; 213:660–5. 92. Mehta A, Lu X, Block T, Blumberg B, Dwek R. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single Nlinked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A. 1997; 94:1822–27. 93. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology. 2007; 45: 277-85. 94. Chen J, Liu Y, Zhao J, Xu Z, Chen R, Si L, et al. Characterization of Novel Hepatitis B Virus PreS/S-Gene Mutations in a Patient with Occult Hepatitis B Virus Infection. PLoS One. 2016; 16;11(5):e0155654. 95. Gerlich W, Glebe D, Schuttler C. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat. 2007; 14(1):16–21. 96. Huang F-Y, Wong D K-H, Seto W-K, Zhang A-Y, Lee C-K, Lin C-K, et al. Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection. PLoS ONE. 2014; 9(6): e99028. 97. Pollicino T, Amaddeo G, Restuccia A, Raffa, G, Alibrandi A, Cutroneo G, et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology. 2012; 56(2):434-43. 98. Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011; 54: 829-36. 99. Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. 2006; 45: 553-9. 100. Caruntu F, Molagic V. CccDNA persistence during natural evolution of chronic HBVinfection. Rom J Gastroentero. 2005; l14:373–7. 101. Rapicetta M, Ferrari C, Levrero M. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol. 2002; 67:454–7. 102. Kwak M-S, Kim Y S. Occult hepatitis B virus infection World J Hepatol. 2014; 6(12): 860-9. 103. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996; 2: 1104-08. 104. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest. 1996; 98:1185-94. 105. Bes M, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, et al. PT cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol. 2012; 56:765-74. 106. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology. 2008; 134: 1470-81. 107. Coffin CS, Pham TN, Mulrooney PM, Churchill ND, Michalak TI. Persistence of isolated antibodies to woodchuckhepatitis virus core antigen is indicative of occult infection. Hepatology. 2004; 40: 1053-61. 108. Martin CM, Welge JA, Shire NJ, ShataMT, Sherman KE, Blackard JT. Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine. 2009; 47:194–8. 109. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001; 19:65–91. 110. Askari A, Hassanshahi GH, Ghalebi SR, Jafarzadeh A, Mohit M, Hajghani M, et al. Intensity of HLA-A2 Expression Significantly Decreased in Occult Hepatitis B Infection. Jundishapur J Microbiol 2014; 7(6): e10298. 111. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G. Serum Levels of IL-10 and IL-17A in Occult HBV-Infected South-East Iranian Patients. Hepat Mon. 2010; 10: 31-5. 112. Ahmadabadi BN, Hassanshahi G, Arababadi MK, Leanza C, Kennedy D. The IL-10 promoter polymorphism at position -592 is correlated with susceptibility to occult HBV infection. Inflammation. 2012; 35: 818-21. 113. Koumbi L, Karayiannis P The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection. Frontiers in Microbiology. 2016; 6:1491-501. 114. Vivekanandan P, Thomas D, Torbenson M, Methylation Regulates Hepatitis B Viral Protein Expression. J Infect Dis. 2009; 199(9): 1286–91. 115. Zhang Y, Mao R, Yan R, Cai D, Zhang Y, Zhu H, et al. Transcription of Hepatitis B Virus Covalently Closed Circular DNA Is Regulated by CpG Methylation during Chronic Infection. PLOS ONE 2014; 9 : e110442-48. 116. Tropberger P, Mercier A, Robinson M, Zhong W, Ganem D.E, and Holdorf M. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A. 2015; 112(42): e5715-24. 117. Quasdorff M and U. Protzer Control of hepatitis B virus at the level of transcription. J Vir Hepat. 2010; 17: 527–36. 118. Bar-Yishay I, Shaul Y, Shlomai A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int. 201; 31:282–90. 119. Vivekanandan P, Kannangai R, Ray SC, Thomas D, Torbenson M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis. 2008; 46:1227–36. 120. Reese VC, Ondracek CR, Rushing CN, Li L, Oropeza CE, McLachlan A. Multiple nuclear receptors may regulate hepatitis B virus biosynthesis during development Int Biochem Cell Biol. 2009; 43:230-7. 121. Li L, Oropeza CE, Sainz JB, Uprichard SL, Gonzalez FJ, McLachlan A. Developmental regulation of hepatitis B virus biosynthesis by hepatocyte nuclear factor 4a. PLoS ONE, 2009; 4: e5489.96. 122. Tang H, McLachlan A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. PNAS. 2001; 98: 1841-6. 123. Guidotti LG, Eggers CM, Raney AK, Chi SY, Peters JM, Gonzalez FJ, et al. In vivo regulation of hepatitis B virus replication by peroxisome proliferators. J Virol. 1999; 73: 10377-86. 124. Lieberman PM. Chromatin organization and virus gene expression. J Cell Physiol. 2008; 216: 295-302. 125. Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J. Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta. 2010; 1799:228-35. 126. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009; 51:581–92. 127. Rall LB, Standring DN, Laub O, Rutter WJ. Transcription of hepatitis B virus by RNA polymerase II. Mol Cell Biol. 1983; 3(10):1766–73. 128. Voss TC, Hager GL Dynamic regulation of transcriptional states by chromatin and transcription factors. Nat Rev Genet. 2014; 15(2):69–81. 129. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA bound H3 and H4 histones. Gastroenterology. 2006; 130:823–37. 130. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004; 126:1750–8. 131. Belloni L, Pollicino T, De NF, Guerrieri F, Raffa G, Fanciulli M, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA: (2009; 106:19975–79. 132. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES. Et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica. 2009; 94: 1618-22. 133. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 2006; 66:8762–69. 134. Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med. 2007; 356:1591-92. 135. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, IFN-á inhibits HBV transcription and replication by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012; 122(2):529-37. 136. Kim J, Lee W, Park SH, Hwang YS, Jeong JH, Kim SH. Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection. Intervirology. 2011; 54:316–25. 137. Kaur P, Paliwal A, Durantel D, Hainaut P, Scoazec JY, Zoulim F, et al. DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis. 2010; 202: 700-04. 138. Vivekanandan P, Thomas D, Torbenson M. Methylation regulates hepatitis B viral protein expression. J Infect Dis. 2009; 199:1286–91. 139. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta. 2010: 1799:694–701. 140. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013; 10(9):542–52. 141. Mizuguchi Y, Takizawa T, Uchida E. Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication. World J Hepatol. 2015; 7(4):696–702. 142. Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antivir Res. 2010; 88:169–175. 143. Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A Human microRNAhsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res. 2011; 39:5157–63. 144. Guo H, Liu H, Mitchelson K, Rao H, LuoM, Xie L. MicroRNAs-372/373 promote the expression of hepatitis B virus through the targeting of nuclear factor I/B. Hepatology. 2011; 54:808–19. 145. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010; 38:5366–83. 146. Kim BK, Lim SO, Park YG. Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis B virus replication. Hepatology. 2008; 48:361–73.